Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) have been given a consensus recommendation of “Moderate Buy” by the nine ratings firms that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $55.2857.

KNSA has been the subject of several recent analyst reports. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Wells Fargo & Company increased their target price on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Wedbush boosted their price target on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Finally, Canaccord Genuity Group started coverage on Kiniksa Pharmaceuticals International in a research report on Thursday, February 19th. They set a “buy” rating and a $62.00 price objective on the stock.

Insider Transactions at Kiniksa Pharmaceuticals International

In related news, Director Barry D. Quart sold 2,690 shares of the stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $45.00, for a total transaction of $121,050.00. Following the transaction, the director owned 12,546 shares in the company, valued at $564,570. This represents a 17.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Mark Ragosa sold 17,845 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $43.28, for a total transaction of $772,331.60. Following the completion of the sale, the chief financial officer directly owned 12,086 shares of the company’s stock, valued at approximately $523,082.08. This trade represents a 59.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 48,605 shares of company stock worth $2,122,646. Insiders own 53.48% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals International

Hedge funds have recently bought and sold shares of the company. USA Financial Formulas purchased a new position in Kiniksa Pharmaceuticals International in the third quarter worth about $32,000. Smartleaf Asset Management LLC bought a new position in shares of Kiniksa Pharmaceuticals International in the 4th quarter worth approximately $36,000. EverSource Wealth Advisors LLC lifted its stake in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after purchasing an additional 532 shares during the period. Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Kiniksa Pharmaceuticals International in the fourth quarter worth approximately $41,000. Finally, CIBC Private Wealth Group LLC purchased a new position in shares of Kiniksa Pharmaceuticals International in the fourth quarter worth approximately $41,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Trading Up 1.4%

Kiniksa Pharmaceuticals International stock opened at $48.82 on Friday. Kiniksa Pharmaceuticals International has a 12 month low of $18.25 and a 12 month high of $49.33. The company has a market capitalization of $3.74 billion, a price-to-earnings ratio of 65.97 and a beta of 0.06. The business’s fifty day simple moving average is $45.40 and its two-hundred day simple moving average is $41.77.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.12). The company had revenue of $202.13 million during the quarter, compared to analysts’ expectations of $200.86 million. Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.Kiniksa Pharmaceuticals International’s revenue for the quarter was up 65.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.12) EPS. On average, equities research analysts predict that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.